Clinical complications of antiretroviral therapy in HIV/TB patients in referral hospital, China

被引:1
作者
Li, Ziyuan [1 ]
Du, Shuxu [2 ]
Xiao, Zhengyun [1 ]
Xiao, Jiang [3 ]
机构
[1] Wuhan Iron & Steel Corp WISCO, Workers Hosp Huarun WISCO Hosp, Baiyushan St, Wuhan 430085, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, 10 Tieyi Rd, Beijing 100020, Peoples R China
[3] Capital Med Univ, Beijing Ditan Hosp, Natl Clin Key Dept Infect Dis, 8 Jingshun East St, Beijing 100015, Peoples R China
关键词
AIDS; complication; HAART; HIV; risk factor; tuberculosis; RECONSTITUTION INFLAMMATORY SYNDROME; INFECTED PATIENTS; PULMONARY TUBERCULOSIS; DRUG-INTERACTIONS; RISK-FACTORS; MORTALITY; MENINGITIS; INITIATION; EFAVIRENZ; FREQUENCY;
D O I
10.2217/fvl-2016-0102
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Aim: The aim was to highlight the clinical complications and to evaluate risk factors of mortality in Chinese HIV/TB patients. Methods: The etiology of clinical deterioration of Chinese HIV/TB patients were evaluated in 180 HIV-infected patients admitted in the Beijing Ditan Hospital between 1 January 2012 and 30 April 2014. Results & conclusion: AIDS-defining illnesses (20.0%) were the most common complication, followed by TB-associated immune reconstitution inflammatory syndrome (16.6%), drug-induced liver injury (11.1%), drug rash (11.1%), non-AIDS-defining illness (5.6%), as well as highly active antiretroviral therapy resistance (3.3%). The risk factors for mortality were tuberculous meningitis associated immune reconstitution inflammatory syndrome (OR: 152.614; CI: 18.324-1263.615; p < 0.001) and non-AIDS-defining illnesses (OR: 114.133; CI: 12.939-1006.752; p < 0.001), which will help remind physicians of the risk of clinical deterioration in HIV/TB patients after antiretroviral therapy in China.
引用
收藏
页码:67 / 78
页数:12
相关论文
共 36 条
  • [1] Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
    Aithal, G. P.
    Watkins, P. B.
    Andrade, R. J.
    Larrey, D.
    Molokhia, M.
    Takikawa, H.
    Hunt, C. M.
    Wilke, R. A.
    Avigan, M.
    Kaplowitz, N.
    Bjornsson, E.
    Daly, A. K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) : 806 - 815
  • [2] [Anonymous], 2017, Global tuberculosis report
  • [3] [Anonymous], GUID US ANT AG HIV 1
  • [4] Determinants of immune reconstitution inflammatory syndrome in HIV type 1 -: Infected patients with tuberculosis after initiation of antiretroviral therapy
    Breton, G
    Duval, X
    Estellat, C
    Poaletti, X
    Bonnet, D
    Mvondo, DM
    Longuet, P
    Leport, C
    Vildé, JL
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (11) : 1709 - 1712
  • [5] Burman W, 2007, INT J TUBERC LUNG D, V11, P1282
  • [6] *CDCP, UPD GUID US RIF TREA
  • [7] Collins Kalonji R., 2002, AIDS Reviews, V4, P165
  • [8] The Rising Challenge of Non-AIDS-Defining Cancers in HIV-Infected Patients
    Deeken, John F.
    Tjen-A-Looi, Angelique
    Rudek, Michelle A.
    Okuliar, Catherine
    Young, Mary
    Little, Richard F.
    Dezube, Bruce J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 55 (09) : 1228 - 1235
  • [9] TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality
    Efsen, Anne Marie W.
    Panteleev, Alexander M.
    Grint, Daniel
    Podlekareva, Daria N.
    Vassilenko, Anna
    Rakhmanova, Aza
    Zeltina, Indra
    Losso, Marcelo H.
    Miller, Robert F.
    Girardi, Enrico
    Cayla, Joan
    Post, Frank A.
    Miro, Josem.
    Bruyand, Mathias
    Furrer, Hansjakob
    Obel, Niels
    Lundgren, Jens D.
    Mocroft, Amanda
    Kirk, Ole
    [J]. BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [10] Immune restoration disease after antiretroviral therapy
    French, MA
    Price, P
    Stone, SF
    [J]. AIDS, 2004, 18 (12) : 1615 - 1627